somatropin, rDNA origin, for injection
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Growth Disorder
Conditions
Growth Disorder
Trial Timeline
Feb 1, 2001 → Jan 1, 2006
NCT ID
NCT00191074About somatropin, rDNA origin, for injection
somatropin, rDNA origin, for injection is a phase 3 stage product being developed by Eli Lilly for Growth Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00191074. Target conditions include Growth Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00191074 | Phase 3 | Completed |
Competing Products
20 competing products in Growth Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Somatropin | Eli Lilly | Phase 3 | 77 |
| Somatropin (recombinant deoxyribonucleic acid [rDNA] origin) | Eli Lilly | Pre-clinical | 23 |
| HER3-DXd | Daiichi Sankyo | Pre-clinical | 23 |
| Erlotinib | Astellas Pharma | Phase 2 | 52 |
| radio-labeled naquotinib + naquotinib | Astellas Pharma | Phase 1 | 33 |
| pegylated Somatropin + pegylated Somatropin + Jintropin AQ | Sun Pharmaceutical | Phase 2 | 52 |
| PEG-somatropin | Sun Pharmaceutical | Approved | 85 |
| PEG-somatropin + PEG-somatropin | Sun Pharmaceutical | Approved | 85 |
| PEG-somatropin | Sun Pharmaceutical | Phase 3 | 77 |
| Somatropin + Somatropin | Eli Lilly | Phase 3 | 77 |
| Somatropin + Somatropin | Eli Lilly | Phase 3 | 77 |
| Sterile becaplermin gel vs. sterile placebo gel treatment 1 | Johnson & Johnson | Pre-clinical | 23 |
| ABT-414 | AbbVie | Pre-clinical | 23 |
| Saizen® A + Saizen® B | Merck | Phase 3 | 77 |
| Saizen® solution for injection (referred as Saizen®) | Merck | Approved | 85 |
| Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) | Merck | Phase 3 | 77 |
| Saizen + Saizen | Merck | Approved | 85 |
| Miransertib | Merck | Phase 2 | 52 |
| Miransertib | Merck | Phase 1/2 | 41 |
| ARX201 + ARX201 + ARX201 | Merck | Phase 2 | 52 |